Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 50,05 € (+16,88 %). Medianen er 50,50 € (+17,94 %).

Køb
  5
Behold
  1
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • HeartFlow: plaque analysis becomes main growth driver

    HeartFlow presented plaque analysis as its most important near-term growth driver at the Wells Fargo conference and projects about $30 million in revenue for 2026 versus $1.5 million in 2025. In Q2 2026 revenue rose 48% to over $64 million with a gross margin of roughly 82%. The company has about $250 million in cash, aims for profitability by mid-2028, and sees an expanded addressable market from $5 billion to $11 billion through expansion into asymptomatic high-risk patients; a broader product rollout including PCI Navigator is planned for 2027. » Mere på de.investing.com


  • Heartflow climbs to new record high of $51.26

    Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » Mere på de.investing.com


  • Heartflow hits record high of $48.70 after strong Q2 results

    Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » Mere på de.investing.com


  • HeartFlow beats Q2 expectations, raises full-year guidance and stock jumps after hours

    HeartFlow reported an adjusted loss per share of $0.07 for Q2 2026, beating consensus by $0.12. Revenue rose 48% to $64.1 million and gross margin climbed to 83.3%, driven by strong plaque business and AI-powered automation. The company raised its full-year guidance to $246–250 million in revenue and a non-GAAP gross margin of about 82%; the stock rose roughly 16–17% after hours. While HeartFlow remains unprofitable, it expects to be cash-flow positive by mid-2028 and is showing accelerated revenue and margin growth. » Mere på de.investing.com


  • HeartFlow beats Q1 forecasts, raises full-year outlook — shares slightly weaker

    HeartFlow reported Q1 2026 EPS of -$0.16, beating the expected -$0.22; revenue rose 41% to $52.6 million. Non-GAAP gross margin improved to 80.5% and the non-GAAP net loss narrowed to $13.3 million. The company received positive feedback on new products such as the PCI Navigator and raised its 2026 revenue guidance to $228–232 million. Despite the results, the stock slipped 0.61% in after-hours trading. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde HeartFlow en omsætning på 64,32 mio. € og et nettoresultat på -10,16 mio. €
(EUR) september 2026
YoY
Omsætning 64,32 mio. 63,12 %
Bruttofortjeneste 53,78 mio. 78,21 %
Nettoresultat -10,16 mio. 76,56 %
EBITDA -10,13 mio. 73,74 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
3,73 mia. €
Antal aktier
87,89 mio.
Højeste/laveste i 52 uger
55,20 € - 18,32 €
Udbytte Nej
Beta
2,02
P/E (PE Ratio)
-50,70
PEG (PEG Ratio)
-0,81
K/I (PB Ratio)
14,40
P/S (PS Ratio)
17,18

Virksomhedsprofil

HeartFlow, Inc., et medicinteknologisk selskab, leverer non-invasive løsninger til diagnosticering og behandling af koronare hjertekarsygdomme over hele verden. Dets HeartFlow Platform bruger AI og beregningsmæssig væskedynamik (computational fluid dynamics) til at skabe en personlig 3D-model af en patients hjerte ud fra en enkelt koronar computertomografi-angiografi, en specialiseret type scanning, der giver detaljerede billeder af hjertets arterier. Selskabets platform giver indsigt i blodgennemstrømning, stenose og plaquevolumen og -sammensætning ved at overvinde begrænsningerne ved traditionelle non-invasive billeddiagnostiske undersøgelser. Selskabet blev grundlagt i 2007 og har hovedkontor i Mountain View, Californien.

Navn
HeartFlow
CEO
John Farquhar
Websted
Børsnotering
07.08.2025
Medarbejdere 843
🍪

Parqet  bruger cookies. Læs mere